Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount
- PMID: 21179461
- PMCID: PMC3001858
- DOI: 10.1371/journal.pone.0014322
Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount
Abstract
The ethical dimensions of pharmacological cognitive enhancement have been widely discussed in academic circles and the popular media, but missing from the conversation have been the perspectives of physicians - key decision makers in the adoption of new technologies into medical practice. We queried primary care physicians in major urban centers in Canada and the United States with the aim of understanding their attitudes towards cognitive enhancement. Our primary hypothesis was that physicians would be more comfortable prescribing cognitive enhancers to older patients than to young adults. Physicians were presented with a hypothetical pharmaceutical cognitive enhancer that had been approved by the regulatory authorities for use in healthy adults, and was characterized as being safe, effective, and without significant adverse side effects. Respondents overwhelmingly reported increasing comfort with prescribing cognitive enhancers as the patient age increased from 25 to 65. When asked about their comfort with prescribing extant drugs that might be considered enhancements (sildenafil, modafinil, and methylphenidate) or our hypothetical cognitive enhancer to a normal, healthy 40 year old, physicians were more comfortable prescribing sildenafil than any of the other three agents. When queried as to the reasons they answered as they did, the most prominent concerns physicians expressed were issues of safety that were not offset by the benefit afforded the individual, even in the face of explicit safety claims. Moreover, many physicians indicated that they viewed safety claims with considerable skepticism. It has become routine for safety to be raised and summarily dismissed as an issue in the debate over pharmacological cognitive enhancement; the observation that physicians were so skeptical in the face of explicit safety claims suggests that such a conclusion may be premature. Thus, physician attitudes suggest that greater weight be placed upon the balance between safety and benefit in consideration of pharmacological cognitive enhancement.
Conflict of interest statement
Figures


Similar articles
-
The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults: The Clinical and Ethical Debates.J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):100-102. doi: 10.1097/JCP.0000000000001336. J Clin Psychopharmacol. 2021. PMID: 33666399
-
Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals.EMBO Rep. 2011 Mar;12(3):197-201. doi: 10.1038/embor.2011.15. Epub 2011 Feb 11. EMBO Rep. 2011. PMID: 21311560 Free PMC article.
-
Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.Lancet Psychiatry. 2015 Apr;2(4):357-62. doi: 10.1016/S2215-0366(15)00004-8. Epub 2015 Mar 31. Lancet Psychiatry. 2015. PMID: 26360089
-
Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?CNS Drugs. 2020 Oct;34(10):1045-1062. doi: 10.1007/s40263-020-00758-w. CNS Drugs. 2020. PMID: 32794136 Review.
-
In search of optimal psychoactivation: stimulants as cognitive performance enhancers.Arh Hig Rada Toksikol. 2019 Sep 1;70(3):150-159. doi: 10.2478/aiht-2019-70-3298. Arh Hig Rada Toksikol. 2019. PMID: 32597132 Review.
Cited by
-
Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals.EMBO Rep. 2013 Feb;14(2):123-8. doi: 10.1038/embor.2012.225. Epub 2013 Jan 15. EMBO Rep. 2013. PMID: 23318628 Free PMC article. No abstract available.
-
To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students.PLoS One. 2013 Nov 13;8(11):e77967. doi: 10.1371/journal.pone.0077967. eCollection 2013. PLoS One. 2013. PMID: 24236008 Free PMC article.
-
Concept generation of cognitive enhancement: healthcare professionals' approach towards the impact and utilization of cognitive enhancers in academic context.Heliyon. 2021 Oct 4;7(10):e08118. doi: 10.1016/j.heliyon.2021.e08118. eCollection 2021 Oct. Heliyon. 2021. PMID: 34660928 Free PMC article.
-
Professionals' attitudes towards the use of cognitive enhancers in academic settings.PLoS One. 2020 Nov 20;15(11):e0241968. doi: 10.1371/journal.pone.0241968. eCollection 2020. PLoS One. 2020. PMID: 33216781 Free PMC article.
-
Emerging Therapeutic Enhancement Enabling Health Technologies and Their Discourses: What Is Discussed within the Health Domain?Healthcare (Basel). 2013 Jul 25;1(1):20-52. doi: 10.3390/healthcare1010020. Healthcare (Basel). 2013. PMID: 27429129 Free PMC article.
References
-
- Bostrom N. In defense of posthuman dignity. Bioethics. 2005;3:202–214. - PubMed
-
- Fukuyama F. New York: Farrar, Straus and Giroux ; 2002. Our posthuman future: consequences of the biotechnology revolution.256
-
- President's Council on Bioethics. New York: Dana Press ; 2003. Beyond therapy: biotechnology and the pursuit of happiness.400
-
- Hunt E. The role of intelligence in modern society. American Scientist. 1995;83:356–367.
-
- Brooks D. The cognitive age. 2008. The New York Times, 2008 2 May. Available: http://www.nytimes.com/2008/05/02/opinion/02brooks.html. Accessed 2010 4 June.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources